Versant Ventures
Markus Warmuth is an experienced leader in the biotechnology and pharmaceutical sectors, currently serving as a Member of the Board of Directors at Ventus Therapeutics and Chief Executive Officer at Monte Rosa Therapeutics since September 2019. In addition, Markus holds the position of Venture Partner at Versant Ventures and has previously operated as an Independent Board Member at IMV Inc. and Relay Therapeutics. With a rich background that includes the role of President and CEO at H3 Biomedicine and Executive Director at Novartis Institutes for BioMedical Research, Markus has significant expertise in oncology and drug discovery, reinforced by a medical degree from Ludwig-Maximilians-Universität München.
This person is not in any offices
Versant Ventures
1 followers
Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $2.4 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and clinical expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 70 Versant companies have achieved successful acquisitions or IPOs.